<DOC>
	<DOC>NCT00907673</DOC>
	<brief_summary>A 28-week, feasibility study to investigate the safety and efficiency of the Automatic Fluid Shunt in patients with chronic congestive heart failure, ascites and diuretic resistance.</brief_summary>
	<brief_title>The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<criteria>Female or male patients ≥ 18 years of age A clinical diagnosis of chronic congestive heart failure &gt; 6 months At least one episode of documented ADHF during the previous 6 months NYHA functional class IIIIV Circulating levels of NTproBNP ≥ 800 ng/L. Stable, optimized therapy for heart failure for at least 4 weeks prior to enrollment Echocardiography performed within 3 months Detectable ascites by ultrasound and/or computed tomography Diuretic resistance defined as a daily dose of furosemide &gt; 80 mg, torsemide &gt; 40 mg or bumetanide &gt; 2 mg Written informed consent Present or recurring systemic or local infection, such as peritonitis, urinary tract infection, or abdominal skin infection. Ongoing malignant disease with adverse prognosis Evidence of firmly loculated peritoneal effusion. Obstructive uropathy Severely reduced renal function (SCreatinine 300 mol/l) or endstage renal disease requiring dialysis Severe liver disease (ASAT and/or ALAT and/or total bilirubin three times upper limit of normal range laboratory values) Pregnancy Requirement for intravenous inotropes Acute coronary syndrome or any condition requiring emergency treatment Heart disease requiring surgical intervention during the course of the study Any other clinically significant disease that could be adversely affected by study participation judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>